{
  "docId": "019de074-3cc2-7451-b551-f16094d96b35",
  "docSlug": "3309edf11a92b656dd98b92129b54a19",
  "documentTitle": "Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides",
  "authorId": "recursion-pharmaceuticals",
  "authorName": "Recursion Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 114,
  "pageCount": 120,
  "prevPage": 113,
  "nextPage": 115,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a testimonial/quote from a KOL regarding the lack of therapeutic relevance in HCC.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-3cc2-7451-b551-f16094d96b35/114",
  "deckHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35",
  "deckJsonHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35.json",
  "deckAnchorHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35#slide-114",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.07,
        "y": 0.195
      },
      "kind": "image",
      "text": "Gross morphology of HCC tumor",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92a06c75-d86c-4438-a1d4-27d00b72e5de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.23
      },
      "kind": "list",
      "text": "Sustained Wnt signaling is a frequent driver event found across a wide variety of solid tumors. Dysregulation of β-catenin destruction complex due to inactivating mutations in AXIN1/APC leads to sustained Wnt signaling promoting cancer progression and survival. AXIN1/APC mutant solid tumors are considered clinically aggressive and resistant to standard treatments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03ec40bd-56d5-46ec-b613-f2d2f4a7b437",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "quote",
      "text": "Nothing in HCC has immediate therapeutic relevance and the most common mutations are TERT, TP53, and Wnt (CTNNB1/AXIN1/APC) and combined these alterations define almost 80% of patients and are not targetable",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd6aa46f-368c-46f1-b49c-dc1d619caffd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Bugter, J.M., et al. Nat Rev Cancer, 2021, 21, pp.5-21",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dae438d-9ea5-4fc0-afd0-8a4c91525d21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Disease Overview : AXIN1/APC mutant cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38595ed7-b8af-4e0c-95b2-db6923eab74b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 15,
      "beatId": "136386a5-6141-40a4-88e2-1f9e9bd0026c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 120,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "781e998b-dc37-46ea-ab12-3271a3953fda",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 1,
      "objective": "How can Recursion's technology and approach improve drug discovery outcomes?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}